Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 05/21/2026

VERO vs. GCTK, LYRA, SSKN, DYNT, and XAGE

Should you buy Venus Concept stock or one of its competitors? MarketBeat compares Venus Concept with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Venus Concept include GlucoTrack (GCTK), Lyra Therapeutics (LYRA), Strata Skin Sciences (SSKN), Dynatronics (DYNT), and Longevity Health (XAGE). These companies are all part of the "medical equipment" industry.

How does Venus Concept compare to GlucoTrack?

GlucoTrack (NASDAQ:GCTK) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. GlucoTrack's return on equity of -581.98% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Venus Concept	-92.76%	-1,904.25%	-85.22%

GlucoTrack has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 2.2% of GlucoTrack shares are owned by company insiders. Comparatively, 28.0% of Venus Concept shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GlucoTrack has higher earnings, but lower revenue than Venus Concept. GlucoTrack is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, GlucoTrack's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
GlucoTrack	Neutral
Venus Concept	Neutral

Summary

GlucoTrack and Venus Concept tied by winning 5 of the 10 factors compared between the two stocks.

How does Venus Concept compare to Lyra Therapeutics?

Lyra Therapeutics (NASDAQ:LYRA) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lyra Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

In the previous week, Lyra Therapeutics' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Venus Concept	Neutral

Venus Concept has a net margin of -92.76% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Venus Concept	-92.76%	-1,904.25%	-85.22%

95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Venus Concept has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	2.22	-$93.43M	-$19.15	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Summary

Lyra Therapeutics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Strata Skin Sciences?

Strata Skin Sciences (NASDAQ:SSKN) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Strata Skin Sciences had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Strata Skin Sciences and 0 mentions for Venus Concept. Strata Skin Sciences' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Strata Skin Sciences	Neutral
Venus Concept	Neutral

Strata Skin Sciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Strata Skin Sciences has a net margin of -35.64% compared to Venus Concept's net margin of -92.76%. Strata Skin Sciences' return on equity of -476.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Skin Sciences	-35.64%	-476.73%	-33.49%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Skin Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Strata Skin Sciences has higher earnings, but lower revenue than Venus Concept. Strata Skin Sciences is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Skin Sciences	$30.98M	0.03	-$10.09M	-$1.41	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

32.4% of Strata Skin Sciences shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 40.9% of Strata Skin Sciences shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Strata Skin Sciences beats Venus Concept on 9 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Dynatronics?

Venus Concept (NASDAQ:VERO) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Dynatronics	-8.35%	-41.81%	-9.56%

Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dynatronics has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Dynatronics	Neutral

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by insiders. Comparatively, 2.9% of Dynatronics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Dynatronics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Longevity Health?

Longevity Health (NASDAQ:XAGE) and Venus Concept (NASDAQ:VERO) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Longevity Health has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Longevity Health has higher earnings, but lower revenue than Venus Concept. Longevity Health is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.51	-$10.37M	-$4.29	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Longevity Health's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Longevity Health	Neutral
Venus Concept	Neutral

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Venus Concept has a net margin of -92.76% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Longevity Health and Venus Concept tied by winning 6 of the 12 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$442K	$7.11B	$6.39B	$12.31B
Dividend Yield	N/A	1.64%	2.76%	5.30%
P/E Ratio	-0.01	47.45	21.14	25.65
Price / Sales	0.01	73.16	553.12	86.87
Price / Cash	N/A	25.14	44.57	56.72
Price / Book	0.07	6.45	10.35	7.12
Net Income	-$47M	$158.81M	$3.56B	$335.28M
7 Day Performance	N/A	3.48%	4.91%	2.66%
1 Month Performance	N/A	-1.90%	1.51%	1.39%
1 Year Performance	-86.01%	1.97%	36.04%	35.43%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	N/A	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
GCTK GlucoTrack	0.1908 of 5 stars	$0.74 -4.3%	N/A	-94.5%	$1.50M	N/A	N/A	5	Gap Down
LYRA Lyra Therapeutics	N/A	$0.73 -1.2%	N/A	-85.1%	$1.30M	$600K	N/A	50	Gap Up
SSKN Strata Skin Sciences	0.2138 of 5 stars	$0.16 +24.3%	N/A	-94.0%	$758K	$30.98M	N/A	120
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. GCTK, LYRA, SSKN, DYNT, and XAGE

How does Venus Concept compare to GlucoTrack?

Summary

How does Venus Concept compare to Lyra Therapeutics?

Summary

How does Venus Concept compare to Strata Skin Sciences?

Summary

How does Venus Concept compare to Dynatronics?

Summary

How does Venus Concept compare to Longevity Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. GCTK, LYRA, SSKN, DYNT, and XAGE

How does Venus Concept compare to GlucoTrack?

Is GCTK or VERO more profitable?

Which has more volatility & risk, GCTK or VERO?

Do analysts prefer GCTK or VERO?

Do institutionals & insiders believe in GCTK or VERO?

Which has better earnings and valuation, GCTK or VERO?

Does the media favor GCTK or VERO?

Summary

How does Venus Concept compare to Lyra Therapeutics?

Do analysts recommend LYRA or VERO?

Which has more risk & volatility, LYRA or VERO?

Does the media refer more to LYRA or VERO?

Is LYRA or VERO more profitable?

Do institutionals and insiders believe in LYRA or VERO?

Which has preferable earnings and valuation, LYRA or VERO?

Summary

How does Venus Concept compare to Strata Skin Sciences?

Does the media refer more to SSKN or VERO?

Which has more volatility & risk, SSKN or VERO?

Is SSKN or VERO more profitable?

Do analysts recommend SSKN or VERO?

Which has stronger valuation and earnings, SSKN or VERO?

Do insiders and institutionals believe in SSKN or VERO?

Summary

How does Venus Concept compare to Dynatronics?

Is VERO or DYNT more profitable?

Which has more risk & volatility, VERO or DYNT?

Do analysts rate VERO or DYNT?

Which has higher earnings and valuation, VERO or DYNT?

Does the media prefer VERO or DYNT?

Do insiders & institutionals have more ownership in VERO or DYNT?

Summary

How does Venus Concept compare to Longevity Health?

Which has more risk and volatility, XAGE or VERO?

Which has better earnings & valuation, XAGE or VERO?

Does the media refer more to XAGE or VERO?

Do institutionals and insiders have more ownership in XAGE or VERO?

Is XAGE or VERO more profitable?

Do analysts rate XAGE or VERO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools